Anti-Epileptic Drugs for Pediatrics Market is estimated to be US$ 918.9 million in 2021, and is expected to witness a CAGR of 7.5%

Coherent Market Insights now offers a detailed analysis of the "Anti-Epileptic Drugs for Pediatrics Market" in new research that provides valuable business insights including revenue share, market valuation, and regional spectrum of this vertical. The report is an all-inclusive study of the current market trends, potential drivers and challenges, application landscape, competition situation, and industry-popular growth strategies, which will empower stakeholders to obtain a clear understanding of this domain. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Anti-Epileptic Drugs for Pediatrics Market.

Request Here For Market Latest Insights(PDF): https://www.coherentmarketinsights.com/insight/request-pdf/823

Companies are concentrating on research and development ventures and study the effectiveness of generic medications to find a clarification to difficulties correlated with existing treatment methods of epilepsy in children. In 2017, a second trial carried out in the U.S. FDA-sponsored EQUIGEN project verified that a generic version of lamotrigine is bioequivalent to Lamictal, which is the brand-name form of the drug.

Furthermore, Sunovion presented a supplemental New Drug Application (sNDA) to the U.S Food and Drug Administration (FDA), to use Aptiom (eslicarbazepine acetate) as monotherapy or adjunctive therapy in the treatment of partial-onset seizures (POS) for children in the age group of 4 years and below. Pfizer, Inc. has molecules NCT02072824, NCT01463306, and NCT01747915 for epilepsy in their pipeline. In 2017, Epygenix Therapeutics, Inc. acquired the U.S. FDA consent for orphan drug appellation to EPX-100 and EPX-200 that are meant for the treatment of patients suffering from Dravet syndrome, which is a disastrous form of epilepsy.

The abundance of anti-epilepsy drugs has increased over the last few decades and nine new drugs for the treatment of pediatric epilepsy were introduced in the last decade, as the benefits of the medicines are greater than the subsequent side-effects from the medicine. Third-generation epilepsy drugs are quickly substituting second and first-generation medications, as they are more reliable and more sustainable than the preceding generation drugs. The newer medications have better effectiveness, with much better pharmacokinetic profiles and fewer medicine interactions than the classic first-generation medications.

For instance, the third-generation drugs, UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) have swiftly become commonly used drugs for first-line treatments. Anticonvulsant medications are only the U.S. FDA-approved for seizure disorders among adolescents. Also, the currently available newer anti-seizure drugs have simple pharmacokinetics and more restricted effects on liver metabolism, thus driving the anti-epileptic drugs for the pediatrics market.

Key Takeaways of the Global Anti-epileptic Drugs for Pediatrics Market:

The global anti-epileptic drugs for the pediatrics market is expected to display a CAGR of 7.5% over the estimated period (2019–2027), owing to growing research and development activities by key players.

Among medication types, the 1st generation segment is expected to account for a major revenue share by 2027

Anti-Epileptic Drugs for Pediatrics Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zynerba, Zogenix and Insys Therapeutics.

"Limited Time Offer Buy This Premium Report With Flat USD 2000 OFF"

Purchase This Complete Report - https://www.coherentmarketinsights.com/promo/buynow/823

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.